Key Takeaways
- Formulations surge, API export strong: Formulations grew 82% YoY to ₹41.7 crores, while API exports rose 28.5% YoY; together they crossed ₹100 crores quarterly and now represent ~60% of revenue.
- Profit growth outpaced revenue: PAT grew 26.9% YoY to ₹14.1 crores with margin improving to 8% from 7.5% YoY, driven by a product mix shift toward higher-margin exports and formulations that offset domestic API pressure.
- Cenobamate launch is the new growth lever: Bajaj became the first company in India to launch Cenobamate API tablets, with repeat orders already received from eight B2B partners, signaling early secondary-sales traction.
- Peptide and oncology bets are funded and on schedule: The peptide plant targets commercial production by Q2 FY28 with ₹70–100 crores first-year revenue, while the oncology API plant also starts in FY28 and aims for ~₹200 crores within 2–3 years.
- What to watch next quarter: Whether Cenobamate secondary sales data confirms the early repeat-order signal, the pace of DMF-to-approval conversions in export markets, and any stabilization in domestic API pricing and inventory levels.
Revenue Drivers: Formulations Rebound and Export Momentum
- Formulations delivered the promised recovery: After a soft Q1, the formulations business rebounded 82% YoY to ₹41.7 crores, exactly as management had signaled at the end of the prior quarter.
- API exports crossed a milestone alongside formulations: API export grew 28.5% YoY to ₹62.6 crores, and together the two segments crossed ₹100 crores in quarterly revenue for the first time, now contributing ~60% of total revenue.
- Domestic API moderated under price pressure: Domestic API revenue dipped sequentially to ₹71.6 crores from ₹92 crores in Q1 FY27, though H1 still grew 10.1% YoY; management cited ongoing demand-supply imbalances and expects no meaningful improvement in pricing.
- The export pipeline is built on regulatory filings: Growth in API exports is driven by 110 DMF filings across countries, with 8 CEPs already approved and marketing underway; remaining approvals are expected to convert to business over the next 1–2 years.
- Korea is already converting: 17 products filed in Korea, with some businesses already started; filings are also planned for Brazil and Mexico, and good results are expected in coming years from these DMF investments.
Anil Jain: "As you know, always API is always on pressure. Price pressure is there, even the demand pressure is there. Over the period of time, there not be much improvement in the API pricing. It will be a straight line."
Cenobamate: The Near-Term Differentiator
- First-mover advantage in India: Bajaj became the first company to receive DCGI approval to manufacture and market Cenobamate API tablets across six strengths, launching commercially in September through eight marketing partners.
- Early repeat orders signal traction: Management confirmed repeat orders have already been received from B2B partners, which it interprets as evidence that secondary sales are moving well, though detailed secondary data is not yet available given the September launch.
- The molecule has sticky demand characteristics: Cenobamate is an anti-seizure drug where patients, once started, typically continue treatment, creating a recurring demand profile that supports sustained offtake.
- Initial volumes are elevated by design: Launch quantities were higher than regular requirements because the molecule is new to India, and partners are building initial channel inventory.
- Revenue quantification remains elusive: Management declined to quantify Cenobamate revenue for the next two years, stating only that "it is growing."
Anil Jain: "We do a primary sale. We are into B2B with eight partners. So What is their sale, still we don't have, because we have launched this product in September itself. But the one good thing is that we have got a repeated orders from them, so this clearly shows that their secondary sales are moving very well."
Margins: Mix Shift Offset the Gross Margin Dip
- Gross margin dipped on external shocks but held stable sequentially: Gross margin was 48.3% in Q2, in line with Q1 FY27, though down ~225–250 bps YoY due to the West Asia crisis, container freight increases, and interest rate volatility.
- EBITDA margin improved sequentially despite the headwind: EBITDA margin rose from 17.8% in Q1 to 18.2% in Q2, and H1 EBITDA margin stood at ~18.1%, because the product mix shifted toward higher-margin exports and formulations, including the Cenobamate launch.
- Management is confident margins are defensible: The company cited its vast product mix as a calibration tool to maintain gross and EBITDA margins in coming quarters, even if API pricing pressure persists.
- Inventory build is a deliberate buffer, not a leakage: Inventory increased as a strategic decision to insulate facilities from West Asia disruption; management will continue monitoring the situation, and this buffer also helped offset supply-chain risk.
- Receivables improved: Receivable turnover improved from 145 to 135 days, indicating working-capital discipline alongside the inventory build.
Rohan Parekh: "We are pretty confident of maintaining this gross margin and EBITDA margins. We do have a vast product mix where we can calibrate it much better in the coming quarters so that we are able to maintain it."
Peptides and Oncology: The FY28 Growth Engines
- Peptide plant on track for March 2027 completion: The commercial peptide manufacturing facility will have 250 kg per annum capacity, supported by solid-phase synthesis and fermentation technology, targeting pharmaceutical, nutraceutical, and cosmetic peptides.
- Revenue ramp is back-end loaded: Real turnover from the peptide facility is expected in FY28–FY29, with first-year revenue of ₹70–100 crores and a cumulative ~₹300 crores the following year; customer approvals will take 6–10 months after commercial production starts in Q2 FY28.
- Bajaj is positioning as an API supplier, not a formulation player: Management emphasized that most Indian competitors are entering peptide injectables, while Bajaj's 250 kg API capacity positions it as a supplier to those very formulators, a niche with fewer players.
- Oncology API and formulation plant starts in FY28: The backward- and forward-integrated oncology facility will serve both branded products and CDMO partners; first-year activity will focus on approvals and ramp-up, with ~₹200 crores revenue expected in 2–3 years.
- Backward integration promises margin uplift: Over the next 2–3 years, 60–70% of oncology products will be backward integrated, which management expects will add 10–15% to margins from those products.
- Six peptide APIs are already developed at pilot scale: The pilot plant has six peptide APIs ready, and the new R&D center houses 80+ scientists across API, peptide, oncology, and biotechnology sections, with capacity for 120.
Anil Jain: "But the main key remains is the API. How many manufacturers are there in India who will be manufacturing the API with this capacity of 250 kg. So we believe that we have a very good position with the peptides."
Strategic Build-Out: Facilities, Talent, and the Revenue Mix Ambition
- Three bottlenecks were identified and addressed: Management flagged facilities, regulatory capabilities, and R&D as the three constraints to growth, and has invested in all three: a peptide plant under construction, another plant planned next year, senior regulatory hires, and an expanded R&D center that covers the next 2–3 years of pipeline.
- Senior leadership was strengthened: Five senior appointments were announced, including a COO with 40+ years in pharma operations, heads for institutional sales, global API business, R&D, and branded generics for rest-of-world markets, plus an oncology sales head.
- Formulation exports are being seeded for the medium term: A new business vertical focused on branded generic formulation exports has submitted dossiers in Africa, Myanmar, Philippines, Vietnam, and Latin America; business is expected from this effort in the next two years.
- The revenue mix target is a structural shift: Over the next 3–4 years, management aims to grow formulations from the current ~20–24% of revenue to 45–50%, with API at 50–55%.
- Genrx acquisition adds formulation capacity: NCLT approval was received for the acquisition of Genrx Pharmaceuticals, which is expected to generate ₹200–250 crores in revenue within 2–3 years once the facility starts.
- The Nashik formulation plant adds dosage-form breadth: Expected operational by Q1 FY28, the facility will produce solid oral dosage forms, nasal, oral oncology, nutraceutical, and ointment formats.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 growth and margin | Revenue and profit growth of 10–15%, EBITDA margin of 18–20% | FY27 |
| FY29 revenue and margin target | Revenue of ₹900–1,000 crores, EBITDA margin of 18–21% | FY29 |
| Peptide plant completion | Commercial manufacturing facility with 250 kg/year capacity | 31 March 2027 |
| Peptide first-year revenue | ₹70–100 crores from peptide facility | FY28–29 |
| Peptide cumulative revenue | ~₹300 crores cumulative in the year after FY28–29 | FY29–30 (implied) |
| Oncology plant start | API and formulation plant commencing operations | Q2 FY28 |
| Oncology revenue ramp | ~₹200 crores revenue from oncology facility | Within 2–3 years of start |
| Genrx revenue contribution | ₹200–250 crores from Genrx facility | Within 2–3 years of start |
| Nashik formulation plant | Operational for solid oral dosage and other formats | Q1 FY28 |
| Formulation revenue mix target | Formulations to reach 45–50% of total revenue | 3–4 years |
| Oncology backward integration | 60–70% of oncology products backward integrated, adding 10–15% margin | 2–3 years |
| FY27 capex | Total capex of ₹65–80 crores | FY27 |
| Annual capex thereafter | ₹50–60 crores annually to support ₹1,000 crore target | FY28 onward |
| FY27 operating cash flow | More than ₹30 crores, with improving EBITDA-to-OCF conversion | FY27 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹175.9 cr, up 18.9% YoY and 6.2% QoQ |
| H1 FY27 revenue from operations | ₹341.5 cr, up 15.1% YoY from ₹296.8 cr in H1 FY26 |
| Gross margin | 48.3%, in line with Q1 FY27; gross profit ₹85.4 cr, up 12.4% YoY |
| EBITDA | ₹32.1 cr, up 12.2% YoY and 8.6% QoQ |
| EBITDA margin | 18.2%, improved sequentially from 17.8% |
| H1 FY27 EBITDA margin | 18.1% |
| Profit after tax | ₹14.1 cr, up 26.9% YoY; PAT margin 8% vs 7.5% in Q2 FY26 |
| H1 FY27 PAT | ₹27.8 cr, up 21.1% YoY; PAT margin 8.1% vs 7.7% in H1 FY26 |
| Formulations revenue | ₹41.7 cr, up 82% YoY and 78.8% QoQ |
| API export revenue | ₹62.6 cr, up 28.5% YoY and 25.1% QoQ |
| Domestic API revenue | ₹71.6 cr, vs ₹76.3 cr in Q2 FY26 and ₹92 cr in Q1 FY27 |
| API export plus formulations revenue | Crossed ₹100 cr, now close to 60% of total revenue |
| Net worth | ~₹557 cr as of 30 Sep 2026, up from ₹533 cr in Mar 2026 |
| Debt-to-equity | ~0.5x |
| FY27 capex guidance | ₹65 cr to ₹80 cr |
| FY29 revenue target | ₹900 cr to ₹1,000 cr, with EBITDA margin of 18% to 21% |
| R&D spending | ~2.5% to 3% of revenue |
| CEP filings | 12 filed, 8 approved, 4 under review |
| South Korea KDMF registrations | 17 total, 2 added in Q2 |
| Peptide plant capacity | 250 kg per annum, completion targeted by 31 Mar 2027 |
| Peptide APIs developed at pilot scale | 6 |
| Receivable turnover | 135 days, improved from 145 days |
| H1 FY27 operating cash flow | ~₹15 cr |
| Full FY27 operating cash flow expectation | More than ₹30 cr |